Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ 3 and vascular endothelial growth factor

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1428-1439

  Sun, Xianlei ^a,b   Ma, Teng ^a,b   Liu, Hao ^a,b   Yu, Xinhe ^a,b   Wu, Yue ^a,b   Shi, Jiyun ^a   Jia, Bing ^a,b   Zhao, Huiyun ^a   Wang, Fan ^a,b   Liu, Zhaofei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Angiogenesis; Arginine glycine aspartic acid; Avastin; Molecular imaging; Tumor response

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID TC 99M; BEVACIZUMAB; BEVACIZUMAB IMMUNOGLOBULIN F(AB) FRAGMENT I 125; RADIOPHARMACEUTICAL AGENT; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; FLUORESCENT DYE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; FLUORESCENCE IMAGING; GLIOBLASTOMA; HEART; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; MOLECULAR IMAGING; MOUSE; NEAR INFRARED FLUORESCENCE; NONHUMAN; SPLEEN; STOMACH; ANIMAL; COLONIC NEOPLASMS; HT 29 CELL LINE; INFRARED RADIATION; LONGITUDINAL STUDY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ANIMALS; COLONIC NEOPLASMS; FLUORESCENT DYES; GLIOBLASTOMA; HT29 CELLS; HUMANS; INDOLES; INFRARED RAYS; INTEGRIN ALPHAVBETA3; LONGITUDINAL STUDIES; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OPTICAL IMAGING; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903707221     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2702-1     Document Type: Article

References (37)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-57.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76. (Pubitemid 36749215)
4. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-30. (Pubitemid 29218291)
5. Brooks PC, ClarkRA, Cheresh DA. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science. 1994;264:569-71.
6. Kumar CC. Integrin alphavbeta3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123-31. (Pubitemid 36553584)
7. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S126-38.
8. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S86-103.
9. Liu Z, Wang F. Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside. Curr Mol Med. 2013;13:1-19.
10. Liu S. Radiolabeled cyclic RGD peptides as integrin alphavbeta3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem. 2009;20:2199-213.
11. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des. 2008;14:2943-73.
12. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009;23:377-89.
13. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-96. (Pubitemid 350002890)
14. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-9.
15. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
16. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189-204. (Pubitemid 40326568)
17. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006;47:793-6. (Pubitemid 46768442)
18. 89Zr-bevacizumab PETof early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51:761-7.
19. 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18:6306-14.
20. Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE. Detection of rapalogmediated therapeutic response in renal cancer xenografts using 64Cubevacizumab immunoPET. PLoS One. 2013;8:e58949.
21. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13:603-8. (Pubitemid 35448063)
22. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71:143-53.
23. 18F-labeled alphavbeta3-integrin and alphavbeta5-integrin imaging agent. J Nucl Med. 2011;52:424-30.
24. 18F-FRGD2. J Nucl Med. 2006;47:113-21.
25. 99mTc-G(3)-2P(4)-RGD2 is correlated with integrin alphavbeta3 expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548-55.
26. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 2003;9:123-8. (Pubitemid 36098273)
27. 99mTc-3PRGD 2 in nonhuman primates. Mol Imaging Biol. 2011;13:730-6.
28. 111In-labeled Abegrin in nude mouse models. Mol Imaging Biol. 2011;13:112-20.
29. 99mTc- labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma. Mol Pharm. 2012;9:1409-17.
30. Liu Z, Liu S, Niu G, Wang F, Liu S, Chen X. Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol Imaging. 2010;9:21-9.
31. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging. 2009;36:947-57.
32. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-95. (Pubitemid 36554699)
33. 64Cu-cyclam-RAFT-c(-RGDfK-)4. Angiogenesis. 2012;15:569-80.
34. 18F-FDG PET of response to Abraxane therapy. J Nucl Med. 2011;52:140-6.
35. 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-43.
36. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004;64:8009-14. (Pubitemid 39446936)
37. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging. 2012;2:1-13.